Ikena Oncology Past Earnings Performance
Past criteria checks 0/6
Ikena Oncology's earnings have been declining at an average annual rate of -16.9%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 16.8% per year.
Key information
-16.9%
Earnings growth rate
67.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 16.8% |
| Return on equity | -40.2% |
| Net Margin | -744.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%
Nov 10
Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers
Aug 15Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues
May 20Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?
Apr 29We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully
Jan 06Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth
Aug 06Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts
Mar 23Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 21Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?
Feb 19We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate
Nov 02Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans
Jul 13Revenue & Expenses BreakdownBeta
How Ikena Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 9 | -68 | 25 | 0 |
| 30 Sep 23 | 14 | -63 | 22 | 0 |
| 30 Jun 23 | 19 | -63 | 21 | 0 |
| 31 Mar 23 | 18 | -66 | 21 | 0 |
| 31 Dec 22 | 16 | -69 | 22 | 0 |
| 30 Sep 22 | 30 | -52 | 22 | 0 |
| 30 Jun 22 | 28 | -49 | 22 | 0 |
| 31 Mar 22 | 31 | -41 | 21 | 0 |
| 31 Dec 21 | 31 | -34 | 18 | 0 |
| 30 Sep 21 | 11 | -63 | 16 | 0 |
| 30 Jun 21 | 10 | -55 | 13 | 0 |
| 31 Mar 21 | 9 | -47 | 10 | 0 |
| 31 Dec 20 | 9 | -44 | 9 | 0 |
| 30 Sep 20 | 12 | -23 | 8 | 0 |
| 31 Dec 19 | 14 | -17 | 7 | 0 |
| 31 Dec 18 | 1 | -41 | 3 | 0 |
Quality Earnings: IKNA is currently unprofitable.
Growing Profit Margin: IKNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IKNA is unprofitable, and losses have increased over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare IKNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IKNA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: IKNA has a negative Return on Equity (-40.16%), as it is currently unprofitable.